US EditionNovo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record - Novo Nordisk (NYSE:NVO)
Novo Nordisk's oral Wegovy prescriptions rose to 20,371 in the second week, driven by reduced needle barriers and backlog of prior authorizations, data suggests.
8 Articles
8 Articles
The success of the drug format will depend on the effectiveness of the New being able to win American consumers willing to pay their own money.
Novo Nordisk's Wegovy pill has had an almost flying start with just over 25,000 prescriptions written since its launch on January 5. It's such a solid launch that it beats the launches that Novo Nordisk has...
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record - Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S' (NYSE:NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge. For context, Eli Lilly And Co's (NYSE:LLY) Zepbound hit about 10,000 scripts in week two, while Novo’s original injectable Wegovy barely cleared 1,000. This isn't just a good launch. It's unprecedented velocity. W…
Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock?
Access to this page has been denied because we believe you are using automation tools to browse the website. This may happen as a result of the following: Javascript is disabled or blocked by an extension (ad blockers for example) Your browser does not support cookies Please make sure that…
Coverage Details
Bias Distribution
- 60% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
